Cargando…
Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancer
Cisplatin is a platinum-based first-line drug for treating ovarian cancer. However, chemotherapy tolerance has limited the efficacy of cisplatin for ovarian cancer patients. Research has demonstrated that cisplatin causes changes in cell survival and death signaling pathways through its interaction...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164250/ https://www.ncbi.nlm.nih.gov/pubmed/32322174 http://dx.doi.org/10.1186/s12935-020-01196-w |